US Patent Issued to SPHINGOTEC on June 23 for "Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C" (German Inventors)

ALEXANDRIA, Va., July 15 -- United States Patent no. 12,662,530, issued on June 23, was assigned to SPHINGOTEC GMBH (Hennigsdorf, Germany).

"Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C" was invented by Andrea Sparwasser (Hennigsdorf, Germany), Paul Kaufmann (Berlin) and Joachim Struck (Berlin).

According to the abstract* released by the U.S. Patent & Trademark Office: "Anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment or anti-ADM non-Ig scaffold for the treatment of a critically ill patients suffering from an acute disease or condition resulting in the accelerated the conversion...